Alleviating oxidative stress disorders with pufa derivatives
AssigneeRetrotope, Inc.
InventorMikhail S. Shchepinov
Life of this patent
Estimating the term…
Abstract
Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress associated diseases such as neurological diseases and age-related macular degeneration (AMD).
Claims41
A method of treating or preventing the progression of a neurodegenerative disease comprising
- selecting a subject that has a neurodegenerative disease or is susceptible to a neurodegenerative disease,
- administering an effective amount of isotopically modified polyunsaturated fatty acid, mimetic or ester pro-drug thereof to the subject;
- wherein upon administration, the isotopically modified polyunsaturated fatty acid, mimetic or ester pro-drug thereof is incorporated in brain and/or neuronal tissue of the subject.
A method of treating or preventing the progression of an oxidative disease of the eye comprising
- selecting a subject that has an oxidative disease of the eye or is susceptible to an oxidative disease of the eye,
- administering an effective amount of at least one isotopically modified polyunsaturated fatty acid, mimetic or ester pro-drug thereof to the subject;
- wherein upon administration, the isotopically modified polyunsaturated fatty acid, mimetic or ester pro-drug thereof is incorporated in eye tissue of the subject.
A method comprising
- selecting a subject in need of increased levels of high-density lipoprotein and/or decreased levels of low-density lipoprotein,
- administering an effective amount of isotopically modified polyunsaturated fatty acid, mimetic or ester pro-drug thereof to the subject;
- and
- wherein upon administration, the level of high-density lipoprotein is increased and/or the level of low-density lipoprotein is decreased.
(canceled)
(canceled)
(canceled)
A method of treating an inborn error of metabolism comprising
- selecting a subject that has an inborn error of metabolism,
- administering an effective amount of isotopically modified polyunsaturated fatty acid, mimetic or ester pro-drug thereof to the subject;
- wherein upon administration, the isotopically modified polyunsaturated fatty acid, mimetic or ester pro-drug thereof is incorporated in brain and/or neuronal tissue of the subject.
A polyunsaturated fatty acid composition comprising
- a pharmaceutically acceptable excipient;
- and
- an isotopically modified polyunsaturated fatty acid or ester thereof comprising at least one 13C or at least one deuterium atoms at a bis-allylic position;
- wherein the composition has an isotopic purity in the range of 5% to 99%.
(canceled)
A polyunsaturated fatty acid composition comprising
- naturally occurring polyunsaturated fatty acid, or ester thereof, that are modified chemically to be effective at preventing specific disease mechanisms;
- wherein the chemical modification does not change the elemental composition of the naturally occurring polyunsaturated fatty acid, or ester thereof;
- with the proviso wherein the isotopically modified polyunsaturated fatty acid is not 11, 11, 14, 14, D4-linolenic acid or 11, 11, D2-linoleic acid.
A method comprising
- administering to a subject a sufficient amount of an isotopically modified PUFA, wherein a cell or tissue of the subject maintains a sufficient concentration of isotopically modified PUFAs to maintain autooxidation of the PUFA.
Dependencies are inferred from the claim text.